文献速递银屑病与炎症性皮肤病

司库奇尤单抗治疗甲银屑病2.5年随机对照研究结果

Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study.
PubMed 文献 · Br J Dermatol · 2020-12-16

TRANSFIGURE是一项双盲、随机、安慰剂对照、平行组、多中心IIIb期研究,纳入198例中重度甲银屑病患者,评估司库奇尤单抗150 mg与300 mg的疗效与安全性。

要点

  • 司库奇尤单抗300 mg与150 mg在2.5年内持续改善甲银屑病NAPSI。
  • 2.5年时NAPPA生活质量评分持续临床显著下降。

核心结论

  • 司库奇尤单抗在甲银屑病中显示出强且具临床意义的疗效,可持续长达2.5年,伴显著持续的生活质量改善和良好安全性。
  • 第16周NAPSI主要终点达标,证实司库奇尤单抗优于安慰剂。

研究设计与样本

  • TRANSFIGURE为双盲、随机、安慰剂对照、平行组、多中心IIIb期研究,共纳入198例中重度甲银屑病患者。
  • 研究评估司库奇尤单抗150 mg与300 mg。

主要发现

  • 2.5年时分别有70%(300 mg)与71%(150 mg)患者达到加权NAPPA患者获益指数总体评分≥2。
  • 2.5年时EuroQol 5-Dimension健康状态问卷显示疼痛与不适改善。
  • 未观察到新的安全性发现。

临床怎么用

  • 对中重度甲银屑病患者,司库奇尤单抗可作为兼顾甲损害与生活质量的长期治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, a cornerstone cytokine in psoriasis, has shown long-lasting efficacy and safety in the complete spectrum of psoriasis manifestations. OBJECTIVES: To report the long-term (2·5-year) efficacy and safety of secukinumab in nail psoriasis. METHODS: TRANSFIGURE, a double-blind, randomized, placebo-controlled, parallel-group, multicentre phase IIIb study in 198 patients, investigated secukinumab 150 mg and 300 mg in patients with moderate-to-severe nail psoriasis. RESULTS: At week 16, the primary endpoint Nail Psoriasis Severity Index (NAPSI) was met, demonstrating superiority of secukinumab to placebo. The effect was sustained over 2·5 years with a large benefit for nail clearance, with mean NAPSI improvement of -73·3% and -63·6% with secukinumab 300 mg and 150 mg, respectively. At 2·5 years, secukinumab demonstrated sustained clinically significant reductions in total mean Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) quality-of-life (QoL) scores of -52·4% and -18·1%, and 70% and 71% of patients achieved a weighted NAPPA Patient Benefit Index global score of ≥ 2 with secukinumab 300 mg and 150 mg, respectively. Patients showed considerable improvements in the EuroQol 5-Dimension health status questionnaire at 2·5 years, reporting a decrease in pain and discomfort. No new safety findings were observed. CONCLUSIONS: Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2·5 years in nail psoriasis, with significant sustained QoL improvements and a favourable safety profile.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Reich K, Sullivan J, Arenberger P, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol. 2020. PMID: 32479641. doi:10.1111/bjd.19262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。